zkab001
mAbexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03676959)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802221 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06459687 | Phase 3 | Sep 1, 2024 | Lee's Pharmaceutical |
| NCT04849260 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2021 | Lee's Pharmaceutical |
| NCT04878016 | Phase 3 | Jul 15, 2021 | Lee's Pharmaceutical |
| NCT04608786 | Phase 1 | Dec 1, 2020 | Lee's Pharmaceutical |
| NCT04359550 | Phase 3 | Jun 1, 2020 | Lee's Pharmaceutical |
| NCT04346914 | Phase 1 | Mar 8, 2020 | Lee's Pharmaceutical |
| NCT03676946 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2018 | Beijing Tumor Hospital, Lee's Pharmaceutical |
| NCT03676985 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2018 | Lee's Pharmaceutical |
| NCT03676959 | Phase 1 | Sep 30, 2018 | Chinese Academy of Medical Sciences, Lee's Pharmaceutical |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lee's Pharmaceutical | For profit | 9 | 9 | 3 | 2018 |
| Beijing Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1